UNSPSC 51263503: Hexoprenaline dihydrochloride

This classification denotes an adrenergic beta-2 receptor agonist, bronchodilator agent, and tocolytic agent with the molecular formula C22H32N2O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97TDI0239I, chemically known as benzyl alcohol, .alpha.,.alpha.'-(hexamethylenebis(iminomethylene))bis(3,4-dihydroxy-, dihydrochloride, but more generally known as hexoprenaline dihydrochloride, which bears US NIH Compound Identifier 20321.

European Medicines Agency schedules hexoprenaline dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08041MIG. Most nations, for tariff purposes, schedule hexoprenaline dihydrochloride under HS 29225000. SMILES: C1CC(C(CC1C(CNCCCCCCNCC(C2CCC(C(C2)O)O)O)O)O)O.CL.CL.

UNSPSC 51263503 Hexoprenaline dihydrochloride is a Commodity code with minimal recent state and local procurement activity that clearly aligns with its nominal pharmaceutical scope. The recent opportunities posted under this code do not reflect hexoprenaline procurement; instead, the tagged solicitations cover naloxone (an opioid antagonist) and broader pharmacy benefit program sourcing. State and local governments procure emergency pharmaceuticals and specialized drug products through this code family, but the recent record shows a mismatch between the code's narrow chemical specification and the actual work being solicited.

Activity in the recent-opportunity block centers on Florida and Texas public-health and state-agency purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023, through electronic bidding with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription programs serving self-insured state employee health plans and group purchasing arrangements, signaling early-stage state interest in alternative pharmaceutical sourcing models outside traditional pharmacy benefit manager channels. The code shows limited recent relevant activity; firms pursuing pharmaceutical and emergency-medical-supply contracts should monitor the broader pharmaceutical-products and medical-supplies family codes rather than rely on this narrow commodity classification for market signals.